Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN)

ConditionMetastatic Prostate Cancer

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexMale

Age18-99

SponsorNovartis Pharmaceuticals

About this trial

This non-interventional, observational, multicenter, prospective cohort study is designed to investigate the treatment patterns of mPC patients treated with lutetium (177Lu) vipivotide tetraxetan, as well as their clinical outcomes, real-world characteristics, and quality of life during the treatment period and up to one year after treatment completion.

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

Not listed

Trial groups

170 Participants

are grouped into 2 trial groups

Sponsors and collaborators

Novartis Pharmaceuticals

Lead sponsor

Source ClinicalTrials.gov